Advertisement

Drugs

, Volume 71, Issue 8, pp 1071–1091 | Cite as

Tesamorelin

A Review of its Use in the Management of HIV-Associated Lipodystrophy
  • Sohita DhillonEmail author
Adis Drug Evaluation

Abstract

Tesamorelin (Egrifta™) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat accumulation.

Subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), but did not affect subcutaneous adipose tissue to a clinically significant extent in two 26-week, well designed, clinical trials in patients with HIV-associated central fat accumulation. This reduction in VAT was maintained in the longer term in patients who continued to receive tesamorelin until week 52 in the extension phases of the two trials. However, discontinuation of therapy during this period resulted in the reaccumulation of VAT. Tesamorelin therapy was also associated with significant improvements in other body composition measures (e.g. trunk fat and waist circumference) and improvements were generally seen in some body image parameters (e.g. belly image distress). Tesamorelin was generally well tolerated, with treatment-emergent serious adverse events occurring in <4% of patients during 26 weeks of therapy. Most of these events were injection-site reactions or events known to be associated with growth hormone therapy (e.g. arthralgia, headache and peripheral oedema). Although long-term clinical experience is needed to further assess the benefits and risks of therapy, current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image.

Keywords

Growth Hormone Placebo Recipient Visceral Adipose Tissue Growth Hormone Secretion Extension Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wierzbicki AS, Purdon SD, Hardman TC, et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res & Opin 2008; 24(3): 609–24CrossRefGoogle Scholar
  2. 2.
    Lohse N, Hansen AB, Gerstoft J, et al. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007 Sep; 60(3): 461–3PubMedCrossRefGoogle Scholar
  3. 3.
    Benedini S, Terruzzi I, Lazzarin A, et al. Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy. Biodrugs 2008; 22(2): 101–12PubMedCrossRefGoogle Scholar
  4. 4.
    Gazzard BG, Anderson J, Babiker A, et al. on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008 Oct; 9(8): 563–608Google Scholar
  5. 5.
    Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999 Mar 11; 13(4): 465–71PubMedCrossRefGoogle Scholar
  6. 6.
    Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 Jun 19; 353(9170): 2093–9PubMedCrossRefGoogle Scholar
  7. 7.
    van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001 May 4; 15(7): 847–55PubMedCrossRefGoogle Scholar
  8. 8.
    Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis 2011 Feb; 24(1): 43–9PubMedCrossRefGoogle Scholar
  9. 9.
    Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001 Feb; 86(2): 504–10PubMedCrossRefGoogle Scholar
  10. 10.
    Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12-week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007 Jul 1; 45(3): 286–97PubMedGoogle Scholar
  11. 11.
    Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008 Aug 6; 300(5): 509–19PubMedCrossRefGoogle Scholar
  12. 12.
    Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004 Jul 14; 292(2): 210–8PubMedCrossRefGoogle Scholar
  13. 13.
    Theratechnologies Inc. Egrifta™ (tesamorelin for injection): US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2011 Feb 8]
  14. 14.
    Theratechnologies. FDA approves Egrifta™ (tesamorelin for injection): the first and only treatment for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [media release]. 2010 Nov 11 [online]. Available from URL: http://www.theratech.com
  15. 15.
    Michaud SE, Abolfathi Z, Potvin D, et al. Pharmacokinetic/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone-releasing factor analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations [poster no. P3-641]. 91st Annual Meeting of the Endocrine Society; 2009 Jun 10–13; Washington, DCGoogle Scholar
  16. 16.
    Mamputu JC, Soulban G, Falutz J. Effects of tesamorelin, a growth hormone-releasing factor (GRF) analogue, on bone turnover markers in HIV-infected patients with excess abdominal fat [abstract no. 834 plus poster presentation]. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27–Mar 2; Boston (MA)Google Scholar
  17. 17.
    Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2011 Feb 9]
  18. 18.
    Center for Drug Evaluation and Research. Pharmacology review(s) [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2011 Feb 9]
  19. 19.
    Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009 Apr; 30(2): 152–77PubMedCrossRefGoogle Scholar
  20. 20.
    Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007 Jan; 100(1): 49–58PubMedCrossRefGoogle Scholar
  21. 21.
    Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005 Aug 12; 19(12): 1279–87PubMedCrossRefGoogle Scholar
  22. 22.
    Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011 Jan; 96(1): 150–8PubMedCrossRefGoogle Scholar
  23. 23.
    Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007 Dec 6; 357(23): 2359–70PubMedCrossRefGoogle Scholar
  24. 24.
    Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010 Mar 1; 53(3): 311–22PubMedCrossRefGoogle Scholar
  25. 25.
    Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008 Sep 12; 22(14): 1719–28PubMedCrossRefGoogle Scholar
  26. 26.
    Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010 Sep; 95(9): 4291–304PubMedCrossRefGoogle Scholar
  27. 27.
    Center for Drug Evaluation and Research. Medical review(s) [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2011 Feb 15]
  28. 28.
    IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 Jun; 23(6): 579–93CrossRefGoogle Scholar
  29. 29.
    Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32(1): 193–203PubMedCrossRefGoogle Scholar
  30. 30.
    Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on inflammatory markers in HIV Patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. Epub 2011 Apr 21Google Scholar
  31. 31.
    Vincent G, Teng S, Ducharme MP, et al. Impact of tesamorelin (TH9507), a stabilized growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers [poster no. P178]. 18th Annual Canadian Conference on HIV/AIDS Research; 2009 Apr 23–26; Vancouver (BC)Google Scholar
  32. 32.
    Zoltowska M, Morin J, Glyman S, et al. Efficacy and long-term safety of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue, in sub-populations of HIV-infected patients with excess abdominal fat [poster no. H-228]. 50th International Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12–15; Boston (MA)Google Scholar
  33. 33.
    Falutz J, Mamputu JC, Marsolais C, et al. Atherogenic lipid profile in treated HIV patients with increased visceral adiposity: association with more severe CVD risk parameters and response to tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue [poster no. 713]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal (QC)Google Scholar
  34. 34.
    Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 2007 May; 85(5): 1197–202PubMedGoogle Scholar
  35. 35.
    Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994 Mar 1; 73(7): 460–8PubMedCrossRefGoogle Scholar
  36. 36.
    Savgan-Gurol E, Bredella M, Russell M, et al. Waist to hip ratio and trunk to extremity fat (DXA) are better surrogates for IMCL and for visceral fat respectively than for subcutaneous fat in adolescent girls. Nutr Metab (Lond) 2010; 7: 86CrossRefGoogle Scholar
  37. 37.
    Center for Drug Evaluation and Research. Summary review [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2011 Feb 22]
  38. 38.
    Guaraldi G, Murri R, Orlando G, et al. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev 2008 Jul 30; 10(3): 152–61PubMedGoogle Scholar
  39. 39.
    Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS 2008 Jul; 22(7): 577–85PubMedCrossRefGoogle Scholar
  40. 40.
    Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2009 Apr; 30(7): 850–6PubMedCrossRefGoogle Scholar
  41. 41.
    Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008 May 1; 48(1): 44–52PubMedCrossRefGoogle Scholar
  42. 42.
    Moyle G, Moutschen M, Martinez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010; 12(1): 3–14PubMedGoogle Scholar
  43. 43.
    Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008 Feb; 9(2): 72–81PubMedCrossRefGoogle Scholar
  44. 44.
    European AIDS Clinical Society. Guidelines (version 5–2) [online]. Available from URL: http://www.europeanaidsclinicalsociety.org [Accessed 2011 Feb 17]
  45. 45.
    US Department of Health and Human Services. Lipodystrophy [online]. Available from URL: http://www.aidsinfo.nih.gov [Accessed 2011 Feb 17]
  46. 46.
    Porter SA, Massaro JM, Hoffmann U, et al. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care 2009 Jun; 32(6): 1068–75PubMedCrossRefGoogle Scholar
  47. 47.
    Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004 Mar; 89(3): 1200–6PubMedCrossRefGoogle Scholar
  48. 48.
    Masiá M, Padilla S, Garcia N, et al. Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antivir Ther 2010; 15(1): 101–10PubMedCrossRefGoogle Scholar
  49. 49.
    Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989 Feb; 79(2): 287–91PubMedCrossRefGoogle Scholar
  50. 50.
    Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005 May 1; 39(1): 44–54PubMedCrossRefGoogle Scholar
  51. 51.
    Lekakis J, Tsiodras S, Ikonomidis I, et al. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Sci (Lond) 2008 Sep; 115(6): 189–96CrossRefGoogle Scholar
  52. 52.
    Lekakis J, Ikonomidis I. Cardiovascular complications of AIDS. Curr Opin Crit Care 2010 Oct; 16(5): 408–12PubMedCrossRefGoogle Scholar
  53. 53.
    Deeks SG. Perspective: immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009; 17(4): 118–23PubMedGoogle Scholar
  54. 54.
    Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010 Nov 20; 28(33): 4985–95PubMedCrossRefGoogle Scholar
  55. 55.
    Mateo MG, Gutiérrez MDM, Domingo P, et al. Tesamorelin for the treatment of excess abdominal fat in HIV-1 patients with lipodystrophy. Expert Rev Endocrinol Metab 2011; 6(1): 21–30CrossRefGoogle Scholar
  56. 56.
    Henricsson M, Berntorp K, Fernlund P, et al. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 2002 Feb; 25(2): 381–5PubMedCrossRefGoogle Scholar
  57. 57.
    Falutz J. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies. Curr Opin Clin Nutr Metab Care 2011 May; 14(3): 255–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore, AucklandNew Zealand

Personalised recommendations